ATE258444T1 - Therapeutische chemokine rezeptor antagonisten - Google Patents

Therapeutische chemokine rezeptor antagonisten

Info

Publication number
ATE258444T1
ATE258444T1 AT99908703T AT99908703T ATE258444T1 AT E258444 T1 ATE258444 T1 AT E258444T1 AT 99908703 T AT99908703 T AT 99908703T AT 99908703 T AT99908703 T AT 99908703T AT E258444 T1 ATE258444 T1 AT E258444T1
Authority
AT
Austria
Prior art keywords
therapeutic
treatment
pharmacologically acceptable
cxcr4
provides
Prior art date
Application number
AT99908703T
Other languages
English (en)
Inventor
Ian Clark-Lewis
Jiang-Hong Gong
Vincent Duronio
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002226391A external-priority patent/CA2226391A1/en
Priority claimed from CA002245224A external-priority patent/CA2245224A1/en
Application filed by Univ British Columbia filed Critical Univ British Columbia
Application granted granted Critical
Publication of ATE258444T1 publication Critical patent/ATE258444T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
AT99908703T 1998-03-13 1999-03-12 Therapeutische chemokine rezeptor antagonisten ATE258444T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002226391A CA2226391A1 (en) 1998-03-13 1998-03-13 N-terminal peptides of sdf-1 have functional activities mediated by cxcr4
CA002245224A CA2245224A1 (en) 1998-08-14 1998-08-14 Chemokine receptor antagonists and chemotherapeutics
PCT/CA1999/000221 WO1999047158A2 (en) 1998-03-13 1999-03-12 Therapeutic chemokine receptor antagonists

Publications (1)

Publication Number Publication Date
ATE258444T1 true ATE258444T1 (de) 2004-02-15

Family

ID=25679974

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99908703T ATE258444T1 (de) 1998-03-13 1999-03-12 Therapeutische chemokine rezeptor antagonisten

Country Status (7)

Country Link
US (2) US6946445B1 (de)
EP (1) EP1061944B1 (de)
JP (2) JP2002506830A (de)
AT (1) ATE258444T1 (de)
AU (1) AU762472B2 (de)
DE (1) DE69914463T2 (de)
WO (1) WO1999047158A2 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US20080318855A1 (en) * 1998-03-13 2008-12-25 Chemokine Corporation Dna encoding for recombinant polypeptide emutants of human stromal cell-derived factor 1
JP2002506830A (ja) 1998-03-13 2002-03-05 ザ ユニバーシティ オブ ブリティッシュ コロンビア 治療的ケモカイン受容体アンタゴニスト
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
ES2156581T5 (es) 1998-03-30 2015-01-21 Northwest Biotherapeutics, Inc. Aplicaciones terapéuticas y diagnósticas basadas en el papel del gen CXCR-4 en la tumorigénesis
US6863887B1 (en) 1998-03-30 2005-03-08 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US6949243B1 (en) * 1999-11-24 2005-09-27 Schering Corporation Methods of inhibiting metastasis
US20050059584A1 (en) 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
CA2335109A1 (en) * 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
US7368425B2 (en) 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
US7378098B2 (en) 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
DE60136373D1 (de) 2000-09-05 2008-12-11 Biokine Therapeutics Ltd Neue polypeptide und anti-hiv-arzneimittel, die diese enthalten
AU2001287463A1 (en) * 2000-09-12 2002-03-26 University Of British Columbia Peptide antagonist of multiple chemokine receptors and uses thereof
US7871619B2 (en) * 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7253007B2 (en) 2001-11-30 2007-08-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
EP1503786A2 (de) 2002-05-10 2005-02-09 IPF Pharmaceuticals GmbH Methode zur hemmung der emigration von zellen aus dem intravaskulären kompartiment ins gewebe
AU2003261723A1 (en) 2002-08-27 2004-03-19 Takeda Chemical Industries, Ltd. Cxcr4 antagonist and use thereof
JP4781621B2 (ja) * 2002-08-27 2011-09-28 バイオカイン セラピューティックス リミテッド Ｃｘｃｒ４拮抗薬およびその用途
DE10240064A1 (de) * 2002-08-30 2004-03-11 Universitätsklinikum Freiburg CXCR4-Rezeptor-Antagonisten
CA2522703A1 (en) * 2003-04-16 2004-11-04 Genebact Biotechnologies, Inc. Prophylactic and therapeutic benefits of new class of immune stimulating peptides
WO2004094465A2 (en) * 2003-04-23 2004-11-04 The Board Of Trustees Of The University Of Illinois Office Of Technology Management University Of Illinois At Urbana-Champaign Synthetic molecules that mimic chemokines
WO2005074645A2 (en) * 2004-02-03 2005-08-18 Chemocentryx, Inc. Methods and compositions for modulating angiogenesis
AU2006203826A1 (en) 2005-01-07 2006-07-13 Emory University CXCR4 antagonists for the treatment of HIV infection
WO2006126188A2 (en) 2005-05-25 2006-11-30 Hadasit Medical Research Services And Development Ltd. Cxcr4 antagonists for wound healing and re-epithelialization
JP2009513689A (ja) * 2005-10-31 2009-04-02 ラボラトワール セローノ ソシエテ アノニム 神経学的疾患の治療、及び／又は予防のためのｓｄｆ−１の使用
JP2009531283A (ja) * 2006-02-02 2009-09-03 アラーガン、インコーポレイテッド 眼系疾患の処置のための組成物および方法
JP2009526861A (ja) * 2006-02-14 2009-07-23 ゲイシンガー クリニック 血管新生標的としてのｇｐｃｒ
US8080659B2 (en) 2006-07-11 2011-12-20 Emory University CXCR4 antagonists including diazine and triazine structures for the treatment of medical disorders
US7696309B2 (en) 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
WO2008075371A2 (en) 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
WO2008096359A2 (en) * 2007-02-08 2008-08-14 Rappaport Family Institute For Research In The Medical Sciences Agents for the treatment of multiple sclerosis and methods of using same
US20080214509A1 (en) * 2007-03-02 2008-09-04 Robert Kerbel Methods for enhancing the efficacy of vascular disrupting agents
GB0716897D0 (en) * 2007-08-30 2007-10-10 Univ Muenchen Tech Cancer imaging and treatment
US8440199B2 (en) 2007-12-12 2013-05-14 Imperial Innovations Limited Methods for mobilizing mesenchymal stem cells in a patient
BRPI0909375A2 (pt) 2008-03-28 2015-08-04 Altiris Therapeutics Moduladores de receptores de quimiocinas
BRPI1009663A2 (pt) 2009-06-14 2016-10-11 Biokine Therapeutics Ltd "método para elevação dos níveis plaquetários em um indivíduo com essa necessidade, método de inibição de hemorragia em um indivíduo que a necessite e composição farmacêutica"
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
WO2011106234A1 (en) 2010-02-25 2011-09-01 Provasculon, Inc. Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
JP5522072B2 (ja) 2010-03-04 2014-06-18 株式会社デンソー 車両用通信装置および車両用通信システム
US20130303460A1 (en) * 2011-01-10 2013-11-14 Biokine Therapeutics Ltd. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
KR20140045411A (ko) 2011-05-16 2014-04-16 젠자임 코포레이션 Ｃｘｃｒ４ 길항제의 용도
JP6145089B2 (ja) 2011-06-07 2017-06-07 メソブラスト インターナショナル エスエイアールエル ストロマ細胞由来因子−１のプロテアーゼ耐性変異体を用いた、組織損傷を修復するための方法
EP2841084B1 (de) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptid zur verwendung in der behandlung von lungenkrebs
PL224854B1 (pl) * 2013-08-23 2017-02-28 Univ Warszawski Nowy peptydomimetyk o aktywności antyangiogennej i zawierająca go kompozycja farmaceutyczna
EP3038617A1 (de) 2013-08-30 2016-07-06 Ramot at Tel-Aviv University Ltd. Verfahren zur behandlung amylotropher lateralsklerose durch hemmung der cxcr4/cxcl12-signalisierung
AU2015212341A1 (en) 2014-02-03 2016-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Use of Casein kinase I inhibitors for depleting stem cells
EP3125919A4 (de) * 2014-02-19 2018-01-03 Microconstants China Inc. Chemokinrezeptorantagonist und dessen kombinationstherapie
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
KR102033920B1 (ko) 2016-02-23 2019-10-18 바이오라인알엑스 리미티드 급성 골수성 백혈병을 치료하는 방법
CA3027296A1 (en) * 2016-06-16 2017-12-21 Centre National De La Recherche Scientifique Compounds useful for decreasing interferon level
TWI734027B (zh) * 2017-09-18 2021-07-21 泰宗生物科技股份有限公司 用於治療癌症之組合物
CN108009443A (zh) * 2017-11-30 2018-05-08 广州天鹏计算机科技有限公司 数据的访问方法和系统

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2760992A (en) 1956-08-28 Naphthalene
US2530369A (en) 1948-01-29 1950-11-21 Phillips Petroleum Co Oxidation of aromatic compounds
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IL79289A (en) * 1985-07-05 1992-01-15 Whitehead Biomedical Inst Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
ATE117375T1 (de) 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
US4890286A (en) * 1987-12-11 1989-12-26 Sanyo Electric Co., Ltd. Method and apparatus for decoding error correcting code
WO1989007136A2 (en) 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
CA2064558C (en) 1989-09-25 2001-01-30 Ian B. Pragnell Method for inhibiting growth of stem cells
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
ES2096750T3 (es) 1990-10-31 1997-03-16 Somatix Therapy Corp Vectores retroviricos utiles para la terapia genica.
US5401651A (en) * 1991-10-16 1995-03-28 Walz; Alfred DNA encoding ENA-78, a neutrophil activating factor
WO1993010234A1 (en) 1991-11-15 1993-05-27 The Regents Of The University Of California Therapy of central nervous system by genetically modified cells
US6057123A (en) 1991-12-23 2000-05-02 British Biotech Pharmaceuticals Limited Stem cell inhibiting proteins
EP0691988B1 (de) 1993-03-31 2002-10-02 Pro-Neuron, Inc. Inhibitor der stammzellproliferation und seine verwendung
SG48813A1 (en) 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
WO1995009236A1 (en) 1993-09-28 1995-04-06 The General Hospital Corporation USING ANTISENSE OLIGONUCLEOTIDES TO MODULATE NERVE GROWTH AND TO REVERSE β/A4 AMYLOID-INDUCED MORPHOLOGY
CA2117953C (en) * 1993-10-14 2001-12-11 Tasuku Honjo Human stromal derived factor 1 alpha and 1 beta and dnas encoding the same
US6132987A (en) 1994-01-13 2000-10-17 The Regents Of The University Of California Recombinant mammalian monocyte chemotactic protein-1 (MCP-1) receptors (MCP-1R, CCR-2)
ATE216425T1 (de) 1994-08-13 2002-05-15 Roche Diagnostics Gmbh Verwendung von interferon-gamma zur vermeidung der proliferation und differenzierung der primitiven hämapoietischen vorläuferzellen
US5990163A (en) 1995-01-13 1999-11-23 The Salk Institute For Biological Studies Selective modulation of processes mediated by retinoid X receptors, and compounds useful therefor
US6221361B1 (en) 1995-01-19 2001-04-24 Syntro Corporation Recombinant swinepox virus
US5871723A (en) * 1995-06-06 1999-02-16 The Regent Of The University Of Michigan CXC chemokines as regulators of angiogenesis
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
JPH09206071A (ja) 1996-01-29 1997-08-12 Novo Nordisk As バクテリア由来の酸化酵素
EP0854918A1 (de) * 1996-01-30 1998-07-29 The National Institutes of Health Zellen, die sowohl menschliches cd4 als auch cxcr4 exprimieren
CZ425598A3 (cs) 1996-06-27 1999-08-11 Smithkline Beecham Corporation Antagonista IL-8 receptoru
US6046185A (en) 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
FR2751658B1 (fr) 1996-07-26 1998-10-02 Pasteur Institut Utilisation d'une chemokine (sdf-1) ligand pour le recepteur de lestr/fusin/cxcr4 pour prevenir ou traiter l'infection par des virus de type vih
AR008290A1 (es) 1996-08-15 1999-12-29 Smithkline Beecham Corp Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios.
AU4251197A (en) * 1996-09-06 1998-03-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Therapeutic chemokine antagonists
US5962462A (en) 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US5919776A (en) 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6124319A (en) 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
IT1291353B1 (it) * 1997-05-12 1999-01-07 San Raffaele Centro Fond Peptidi con attivita' antivirale
US6136827A (en) 1997-07-25 2000-10-24 Merck & Co., Inc. Cyclic amine modulations of chemokine receptor activity
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
US6013644A (en) 1997-12-12 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US6140349A (en) 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
JP2002506830A (ja) * 1998-03-13 2002-03-05 ザ ユニバーシティ オブ ブリティッシュ コロンビア 治療的ケモカイン受容体アンタゴニスト
CA2245224A1 (en) * 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
WO2000009152A1 (en) 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
US6613742B1 (en) * 1999-04-07 2003-09-02 Thomas Jefferson University Chemokine-derived synthetic peptides
WO2000066112A1 (en) 1999-05-03 2000-11-09 Smithkline Beecham Corporation Cxcr-4 receptor antagonists - thrombopoietin mimetics
US6356887B1 (en) * 1999-06-28 2002-03-12 Microsoft Corporation Auto-parameterization of database queries
CA2335109A1 (en) * 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
US7378098B2 (en) * 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US20050059584A1 (en) 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
US7091310B2 (en) 2002-09-13 2006-08-15 Chemokine Therapeutics Corporation Chemokine analogs for the treatment of human disease
EP1286684B1 (de) 2000-05-09 2004-04-28 The University Of British Columbia Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
US6639134B2 (en) * 2000-10-03 2003-10-28 Eric T. Schmidt High flow stringed instrument sound hole
US20030202963A1 (en) * 2000-10-12 2003-10-30 Cornell Research Foundation, Inc. Method of treating cancer
US6515001B2 (en) * 2001-03-05 2003-02-04 Chemokine Therapeutic Corporation IL-8 receptor ligands-drugs for inflammatory and autoimmune diseases
US20030004136A1 (en) * 2001-03-05 2003-01-02 Geeta Saxena IL-8 receptor ligands-drugs for inflammatory and autoimmune diseases
US6693134B2 (en) * 2001-05-29 2004-02-17 Chemokine Therapeutics Corporation Bicyclic aromatic chemokine receptor ligands
US6831101B2 (en) * 2001-06-14 2004-12-14 Chemokine Therapeutics Corporation Tricyclic rantes receptor ligands
US20030092674A1 (en) * 2001-06-14 2003-05-15 Geeta Saxena Tricyclic rantes receptor ligands

Also Published As

Publication number Publication date
AU2821699A (en) 1999-10-11
JP2010047598A (ja) 2010-03-04
US7423011B2 (en) 2008-09-09
DE69914463T2 (de) 2004-11-11
WO1999047158A3 (en) 1999-11-25
US20050265969A1 (en) 2005-12-01
EP1061944B1 (de) 2004-01-28
AU762472B2 (en) 2003-06-26
WO1999047158A2 (en) 1999-09-23
DE69914463D1 (en) 2004-03-04
US6946445B1 (en) 2005-09-20
JP2002506830A (ja) 2002-03-05
EP1061944A2 (de) 2000-12-27

Similar Documents

Publication Publication Date Title
ATE258444T1 (de) Therapeutische chemokine rezeptor antagonisten
RU2008116931A (ru) Применение n-десметилклозапина для лечения нейропсихиатрических заболеваний у людей
CY1118849T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
NO975334L (no) Anvendelse av flavanolignaner for fremstilling av medikamenter med antiproliferativ aktivitet i uterus, ovarium og bryst
WO2001060381B1 (en) Nucleoside analogs with carboxamidine-modified bicyclic base
SE0100568D0 (sv) Compounds
EP0457195A3 (en) Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same
IL147852A0 (en) Chemokine receptor antagonists and pharmaceutical compositions containing the same
JP2002523370A5 (de)
CA2444821A1 (en) Combination therapy using anti-angiogenic agents and tnfa
MY139203A (en) Pharmaceutical composition
SE0100566D0 (sv) Compounds
JPH06505483A (ja) サイトカイン阻害剤
EP1392348A1 (de) Niedrigdosierte lhrh antagonisten zur behandlung von neurodegenerativen krankheiten, insbesondere alzheimer krankheit
JP2007119497A (ja) インターフェロン−ガンマスティミュレーター含有医薬組成物
WO1992003145A1 (en) Method of treating viral infection
RU2003100517A (ru) Новый интерферон для лечения рассеянного склероза
MY106603A (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
JP7220489B2 (ja) 炎症性疾患および疼痛を治療するためのペプチドを含有する薬剤
MY143571A (en) Eplerenone crystalline form
EP0999840B1 (de) Verwendung von einem draflazin analog zur schmerzbehandlung
EA200200801A1 (ru) Применение фолликулостимулирующего гормона (fsh) для лечения бесплодия
SE0101692D0 (sv) Compounds
DE69830176D1 (de) Arzneimittel gegen infertilität, die mit endometriose assoziiert ist
FR2791894B1 (fr) Utilisation d'interferon beta dans le traitement de la tumeur d'ewing

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties